CFO appointment
Kalaris Therapeutics, Inc. appoints Liisa Bayko as CFO
Kalaris Therapeutics, Inc. reported in a Form 8-K filed July 20, 2026 that Liisa Bayko was appointed Chief Financial Officer and Treasurer, effective July 20, 2026.
In the filing's words
On July 16, 2026, the Board of Directors (the “Board”) of Kalaris Therapeutics, Inc. (the “Company”) appointed Liisa Bayko as Chief Financial Officer and Treasurer of the Company, effective as of July 20, 2026 (the “Effective Date”). In addition, Ms. Bayko will serve as the Company’s principal financial officer.
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | Kalaris Therapeutics, Inc. (KLRS) |
|---|---|
| Event | Appointment |
| Incoming | Liisa Bayko |
| Title in the filing | Chief Financial Officer and Treasurer |
| Effective | July 20, 2026 |
| 8-K filed | July 20, 2026 |
| Internal promotion | No |
| Prior role (per filing) | Managing Director, Biotech Equity Research, Evercore ISI |
| SEC CIK | 0001754068 |
Kalaris Therapeutics, Inc. reported this change in a Form 8-K, Item 5.02, filed July 20, 2026. The filing's own words are quoted above.
Same industry, July 2026
4Other moves filed that month at companies the roster files under SIC “Biological Products, (No Diagnostic Substances)”.
3 months ago· 2026-07-31AppointmentQNCX
Quince Therapeutics, Inc. appoints John Militello as CFO
3 months ago· 2026-07-27TransitionDTIL
Precision BioSciences, Inc. CFO transition: Naresh Tanna to succeed Alex Kelly
3 months ago· 2026-07-23TransitionIMA
ImageneBio, Inc. CFO transition: Yanina Grant-Huerta to succeed Kristin Yarema, Ph.D.
3 months ago· 2026-07-20AppointmentARMP
Armata Pharmaceuticals, Inc. appoints David House as CFO
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-09-26
Something wrong about Liisa Bayko? Send a correction with the primary source.